×
About 1,483 results

ALLMedicine™ Androgenetic Alopecia Center

Research & Reviews  474 results

A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
https://clinicaltrials.gov/ct2/show/NCT05135468

Jan 14th, 2022 - A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.

Androgenetic Alopecia
http://emedicine.medscape.com/article/1070167-overview

Jan 11th, 2022 - Practice Essentials Androgenetic (or pattern) alopecia is a genetically determined disorder characterized by the gradual conversion of terminal hairs into indeterminate, and finally into vellus, hairs. It is an extremely common disease that affect...

Androgenetic Alopecia Medication
http://emedicine.medscape.com/article/1070167-medication

Jan 11th, 2022 - Medication Summary Only 2 medications have been shown to be effective in the treatment of androgenetic alopecia: minoxidil and finasteride. Minoxidil is applied topically and available as 2% or 5% solutions. Finasteride is taken orally. Next: Vaso...

Androgenetic Alopecia Clinical Presentation
http://emedicine.medscape.com/article/1070167-clinical

Jan 11th, 2022 - History The onset of androgenetic alopecia is gradual. Men present with gradual thinning in the temporal areas, producing a reshaping of the anterior part of the hairline. For the most part, the evolution of baldness progresses according to the No...

Androgenetic Alopecia Treatment & Management
http://emedicine.medscape.com/article/1070167-treatment

Jan 11th, 2022 - Medical Care Only two drugs currently have US Food and Drug Administration (FDA)–approved indications for treatment of androgenetic alopecia: minoxidil and finasteride. Minoxidil Although the method of action is essentially unknown, minoxidil appe...

see more →

Guidelines  2 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

see more →

Drugs  34 results see all →

Clinicaltrials.gov  40 results

A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
https://clinicaltrials.gov/ct2/show/NCT05135468

Jan 14th, 2022 - A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.

A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
https://clinicaltrials.gov/ct2/show/NCT04764331

Jan 4th, 2022 - The purpose of this pilot study is to determine if the Revian Red All LED cap shows potential to be an effective treatment for CCCA by recruiting hair follicles back to anagen growth or by improving inflammation. The primary outcome is to determin...

Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic Alopecia
https://clinicaltrials.gov/ct2/show/NCT05129254

Dec 7th, 2021 - This is a single institution, open-label, baseline-controlled, prospective study evaluating the use of a non-ablative fractionated thulium laser and topical autologous platelet-rich plasma (PRP) vs. PRP injection for the treatment of male androgen...

Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study
https://clinicaltrials.gov/ct2/show/NCT05129800

Nov 22nd, 2021 - Platelet-rich plasma (PRP) has been used for more than a decade in the treatment of androgenetic alopecia and hair loss. Platelets contain a range of growth factors , namely vascular endothelial growth factor (VEGF), insulin-like growth factor (IG...

Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
https://clinicaltrials.gov/ct2/show/NCT04898166

Oct 26th, 2021 - INTRODUCTION: An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019. Belonging to the family Beta-coronavirus, this...

see more →

News  42 results

Common Finding Identified in Patients With Persistent Chemotherapy-Induced Alopecia
https://www.medscape.com/viewarticle/962256

Nov 4th, 2021 - Hair follicle miniaturization was a prominent feature of persistent chemotherapy-induced alopecia (pCIA) in breast cancer survivors who presented to four specialty hair clinics, and treatment with minoxidil (sometimes with antiandrogen therapy) wa...

Hair Regrowth Stimulated by Microneedle Patch
https://www.medscape.com/viewarticle/957481

Aug 30th, 2021 - While some prefer the bald look, those who are unhappy about losing their hair might be interested to hear about a new approach where scientists use mechanical stimulation to promote hair regrowth. Male- or female-pattern baldness, also known as a...

Androgenetic Alopecia Has an Adverse Effect on Emotions, Quality of Life
https://www.medscape.com/viewarticle/956353

Aug 10th, 2021 - Androgenetic alopecia significantly impairs patients' overall quality of life and emotional health, but does not have a notable impact on the incidence of depression, according a systematic review and meta-analysis of 41 studies. "Hair loss affect...

Hair Shedding Related to COVID-19 Doesn't Last Long
https://www.medscape.com/viewarticle/955832

Aug 3rd, 2021 - NEW YORK (Reuters Health) - Acute telogen effluvium (TE) following COVID-19 appears to occur sooner, with quicker resolution, than when TE is triggered by other events, clinicians have observed. TE is form of alopecia characterized by diffuse hair...

Permanent Alopecia in Breast Cancer Patients: Role of Taxanes and Endocrine Therapies
https://www.mdedge.com/dermatology/article/237621/hair-nails
Christa Slaught, MD, Michael Roman, MD et. al.

Mar 24th, 2021 - Anagen effluvium during chemotherapy is common, typically beginning within 1 month of treatment onset and resolving by 6 months after the final course. 1 Permanent chemotherapy-induced alopecia (PCIA), in which hair loss persists beyond 6 months af.

see more →

Patient Education  1 results see all →